
Treatment Guide
Just Diagnosed
Sex & Dating
African American
Stigma
Ask the HIV Doc
PrEP
En Español
News
Voices
Print Issue
Video
Out 100
CONTACT
CAREER OPPORTUNITIES
ADVERTISE WITH US
PRIVACY POLICY
PRIVACY PREFERENCES
TERMS OF USE
LEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use .
The Food and Drug Administration has approved dosing recommendations for Norvir in pediatric patients ages 1 month to 2 years. The recommended dosage is 350 to 400 milligrams twice daily, beginning at 250 milligrams twice per day and increased in 50-milligram increments every two to three days until full dosing levels are reached. Switching from Combivir to Truvada results in a significantly lower virus concentration after six months, according to a study by Gilead Sciences. Patients taking Truvada also experienced increased levels of hemoglobin, which is usually reduced by HIV. A study of 167 treatment-experienced HIV-positive adults has shown that Kaletra maintains durable HIV suppression and increased CD4-cell counts over four years of therapy. The study authors say their results support the use of Kaletra as part of salvage regimens. Results from a 48-week clinical trial have shown that roughly 30% of patients with drug-resistant virus achieved a decrease in HIV viral levels to below 400 copies per milliliter of blood when taking Ritonavir-boosted Aptivus, compared to almost 14% of patients taking other Ritonavir-boosted protease inhibitors. Two key studies of HIV entry inhibitors have been called off because of toxicity issues and poor study results. Pharmaceutical maker GlaxoSmithKline ended Phase III trials of its experimental CCR5 inhibitor aplaviroc after three study subjects developed severe liver toxicity. Schering Plough halted its Phase II study of CCR5 inhibitor vicriviroc when study data showed early viral rebound. Tibotec Therapeutics has expanded access to its experimental protease inhibitor TMC114 after early tests showed the drug is effective against HIV that is resistant to other protease drugs. The colorectal cancer treatment Campto (irinotecan) is effective in treating Kaposi's sarcoma, according to a study that was published in the November 4 edition of the journal AIDS. Researchers found that three quarters of study subjects treated with Campto experienced complete or partial KS remission. Pegylated liposomal doxorubicin used in combination with antiretroviral medications is effective in treating Kaposi's sarcoma , researchers reported in the journal Infection. Nearly 82% of study subjects reported complete or partial KS remission within a median of eight weeks of treatment.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Plus: Featured Video
Latest Stories
The Pride Store: Discover More LGBTQ+ & Ally Brands Tailor Made for Celebrating Your Identity
November 30 2023 3:04 PM
Shop Your Pride: Dive into LGBTQ+ & Ally Brands with The Grand Opening of The Pride Store
November 28 2023 5:32 PM
These Black Queer Podcasts (Featuring Literally Zero Cis White Gay Men) Deserve Your Ears
November 28 2023 11:55 AM
7 Uplifting Films To Celebrate Trans Awareness Week & Where To Stream Them
November 17 2023 10:25 AM
Out's Deal Guide: Grab Your 50% Off Amazon Fire Tablets & More Recommended Deals on Amazon Today!
November 03 2023 3:44 PM
Unlock Massive Savings at 'The Holiday Shop': Amazon's Hottest Deals of the Season Await!
November 02 2023 2:17 PM
Dianne Feinstein’s Commitment to People Living With HIV Won’t Be Forgotten
November 02 2023 1:27 PM
Trending stories
Most Recent
Recommended Stories for You
Plus Editors
Editor
Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.
Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.